# Exploring Autosomal Dominant Non-Syndromic Monogenic Obesity: From Genes to Therapy

**Authors:** Giovanni Luppino, Mara Giordano, Francesca Franchina, Roberto Coco, Eleonora Inì, Carla Fazio, Debora Porri, Cecilia Lugarà, Domenico Corica, Tommaso Aversa, Malgorzata Wasniewska

PMC · DOI: 10.3390/cimb48020162 · 2026-02-01

## TL;DR

This paper reviews autosomal dominant monogenic obesity, focusing on its genetic causes, clinical features, and current treatment challenges.

## Contribution

The paper provides a comprehensive analysis of autosomal dominant non-syndromic monogenic obesity, emphasizing genetic and therapeutic insights.

## Key findings

- Autosomal dominant mutations in genes like MC4R and SH2B1 are linked to non-syndromic monogenic obesity.
- No targeted therapies are currently approved for autosomal dominant monogenic obesity.
- Variants of uncertain significance complicate timely diagnosis and treatment.

## Abstract

Genetic factors are key determinants in the pathophysiology of obesity, regulating energy homeostasis. Monogenic non-syndromic obesity accounts for 2–3% of obesity in both children and adults and is most often attributable to mutations in genes encoding components of the leptin–melanocortin pathway. Genetic testing is indicated in children with severe obesity before age 5, hyperphagia, a family history of obesity, and neurodevelopmental delay or organ dysfunction. Mutations associated with monogenic obesity follow autosomal recessive (LEP, LEPR, POMC, and PCSK1) or autosomal dominant (MC4R, SH2B1, SIM1, GNAS) modes of inheritance. Other gene mutations in heterozygous states (MRAP2, MC3R, SRC1, KSR2) are associated with obesity and may exhibit autosomal dominant inheritance; however, the clinical phenotype depends on the degree of genetic penetrance and interactions with other genetic and/or environmental factors. No approved targeted pharmacotherapies are currently available for autosomal dominant monogenic obesity, and the frequent detection of variants of uncertain significance often hinders timely diagnostic confirmation. The review provides a comprehensive appraisal of autosomal dominant forms of monogenic non-syndromic obesity, analyzing genetic and molecular features, clinical presentations, and therapeutic strategies.

## Linked entities

- **Genes:** LEP (leptin) [NCBI Gene 3952], LEPR (leptin receptor) [NCBI Gene 3953], POMC (proopiomelanocortin) [NCBI Gene 5443], PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122], MC4R (melanocortin 4 receptor) [NCBI Gene 4160], SH2B1 (SH2B adaptor protein 1) [NCBI Gene 25970], SIM1 (SIM bHLH transcription factor 1) [NCBI Gene 6492], GNAS (GNAS complex locus) [NCBI Gene 2778], MRAP2 (melanocortin 2 receptor accessory protein 2) [NCBI Gene 112609], MC3R (melanocortin 3 receptor) [NCBI Gene 4159], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714], KSR2 (kinase suppressor of ras 2) [NCBI Gene 283455]
- **Diseases:** obesity (MONDO:0011122)

## Full-text entities

- **Genes:** PHIP (PHIP subunit of CUL4-Ring ligase complex) [NCBI Gene 55023] {aka BRWD2, CHUJANS, DCAF14, DIDOD, RepID, WDR11}, CCK (cholecystokinin) [NCBI Gene 885], CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, NR3C2 (nuclear receptor subfamily 3 group C member 2) [NCBI Gene 4306] {aka MCR, MLR, MR, NR3C2VIT}, SST (somatostatin) [NCBI Gene 6750] {aka SMST, SST1}, AVP (arginine vasopressin) [NCBI Gene 551] {aka ADH, ARVP, AVP-NPII, AVRP, VP}, ADRA2B (adrenoceptor alpha 2B) [NCBI Gene 151] {aka ADRA2L1, ADRA2RL1, ADRARL1, ALPHA2BAR, FAME2, alpha-2BAR}, NPY (neuropeptide Y) [NCBI Gene 4852] {aka PYY4}, SIM1 (SIM bHLH transcription factor 1) [NCBI Gene 6492] {aka bHLHe14}, GHRH (growth hormone releasing hormone) [NCBI Gene 2691] {aka GHRF, GRF, INN}, OXT (oxytocin/neurophysin I prepropeptide) [NCBI Gene 5020] {aka OT, OT-NPI, OXT-NPI}, KSR2 (kinase suppressor of ras 2) [NCBI Gene 283455], PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, SH2B1 (SH2B adaptor protein 1) [NCBI Gene 25970] {aka PSM, SH2B}, MC4R (melanocortin 4 receptor) [NCBI Gene 4160] {aka BMIQ20}, VN1R17P (vomeronasal 1 receptor 17 pseudogene) [NCBI Gene 441931] {aka GPCR}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}, PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122] {aka BMIQ12, NEC1, PC1, PC1/3, PC3, SPC3}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, GLP1R (glucagon like peptide 1 receptor) [NCBI Gene 2740] {aka GLP-1, GLP-1-R, GLP-1R}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, MC3R (melanocortin 3 receptor) [NCBI Gene 4159] {aka BMIQ9, MC3, MC3-R, OB20, OQTL}, NCOA1 (nuclear receptor coactivator 1) [NCBI Gene 8648] {aka F-SRC-1, KAT13A, RIP160, SRC1, bHLHe42, bHLHe74}, GHR (growth hormone receptor) [NCBI Gene 2690] {aka GHBP, GHIP}, GNAS (GNAS complex locus) [NCBI Gene 2778] {aka AHO, AIMAH1, C20orf45, GNAS1, GPSA, GSA}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, AGRP (agouti related neuropeptide) [NCBI Gene 181] {aka AGRT, ART, ASIP2}, MRAP2 (melanocortin 2 receptor accessory protein 2) [NCBI Gene 112609] {aka C6orf117, bA51G5.2}, IRS2 (insulin receptor substrate 2) [NCBI Gene 8660] {aka IRS-2}, IARS1 (isoleucyl-tRNA synthetase 1) [NCBI Gene 3376] {aka GRIDHH, IARS, ILERS, ILRS, IRS, PRO0785}, MAP2K1 (mitogen-activated protein kinase kinase 1) [NCBI Gene 5604] {aka CFC3, MAPKK1, MEK1, MEL, MKK1, PRKMK1}, MYT1L (myelin transcription factor 1 like) [NCBI Gene 23040] {aka MRD39, NZF1, ZC2H2C2, ZC2HC4B, myT1-L}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, TSHR (thyroid stimulating hormone receptor) [NCBI Gene 7253] {aka CHNG1, LGR3, hTSHR-I}, IRS1 (insulin receptor substrate 1) [NCBI Gene 3667] {aka HIRS-1}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, LEPR (leptin receptor) [NCBI Gene 3953] {aka CD295, LEP-R, LEPRD, OB-R, OBR, huB219}, MC1R (melanocortin 1 receptor) [NCBI Gene 4157] {aka CMM5, MSH-R, SHEP2}, CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915] {aka DEE58, EIEE58, GP145-TrkB, OBHD, TRKB, trk-B}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, PRKAB1 (protein kinase AMP-activated non-catalytic subunit beta 1) [NCBI Gene 5564] {aka AMPK, HAMPKb}, TRH (thyrotropin releasing hormone) [NCBI Gene 7200] {aka Pro-TRH, TRF}, MC5R (melanocortin 5 receptor) [NCBI Gene 4161] {aka MC2}, OXTR (oxytocin receptor) [NCBI Gene 5021] {aka OT-R, OTR}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, MC2R (melanocortin 2 receptor) [NCBI Gene 4158] {aka ACTHR}
- **Diseases:** phosphate abnormalities (MESH:D007015), IR (MESH:D007333), congenital heart disease (MESH:D006330), pituitary hormone deficiencies (MESH:C580003), language and motor delays (MESH:D007805), weight (MESH:D015431), familial glucocorticoid deficiency (FGD) type 2 (MESH:C564577), deletion (MESH:D002872), ADHD (MESH:D001289), endocrine dysfunction (MESH:D004700), neurodevelopmental delay (MESH:D006968), cardiovascular disease (MESH:D002318), menstrual dysfunction (MESH:D004412), SRC1 deficiency (MESH:C564545), SH2B1 deficiency (MESH:D007153), TSH suppression (MESH:D007037), hyperinsulinemia (MESH:D006946), Hypopituitarism (MESH:D007018), polycystic ovary syndrome (MESH:D011085), hypertension (MESH:D006973), intellectual disability (MESH:D008607), hypocalcemia (MESH:D006996), hypotonia (MESH:D009123), Excess (MESH:D006970), enuresis (MESH:D004775), autoimmune hypothyroidism (MESH:C562768), memory deficits (MESH:D008569), cognitive impairment (MESH:D003072), Prader-Willi-like (PWL) syndrome (MESH:C000726748), developmental delay (MESH:D002658), advanced or precocious puberty (MESH:D011629), insufficiency of the growth hormone (GH) axis (MESH:D004393), BBS (MESH:D020788), cardiovascular abnormalities (MESH:D018376), glucose intolerance (MESH:D018149), abnormal appetite regulation (MESH:D001068), dysfunction (MESH:D006331), aggressiveness (MESH:D010554), adipose tissue (MESH:D018205), Endocrine and gynecological-reproductive abnormalities (MESH:D005831), endometrial hyperplasia (MESH:D004714), hormone resistance (MESH:D018382), POMC deficiency (MESH:C565726), T2DM (MESH:D003924), OSAS (MESH:D020181), autosomal dominant and sporadic pseudohypoparathyroidism type 1B (MESH:C548075), schizophrenia (MESH:D012559), PWS (MESH:D011218), liver fibrosis (MESH:D008103), vitiligo (MESH:D014820), resistance (MESH:D060467), adrenal insufficiency (MESH:D000309), diabetes insipidus (MESH:D003919), diabetes (MESH:D003920), NAFLD (MESH:D065626), AD- (MESH:D000544), behavioral abnormalities (MESH:D001523), Short adult stature (MESH:C538052), short stature (MESH:D006130), hypothalamic dysfunction (MESH:D007027)
- **Chemicals:** fatty acid (MESH:D005227), naltrexone (MESH:D009271), Roux (-), T4 (MESH:D013974), glucose (MESH:D005947), T3 (MESH:D014284), lipids (MESH:D008055), triglyceride (MESH:D014280), bupropion (MESH:D016642), fat (MESH:D005223), cAMP (MESH:D000242), cholesterol (MESH:D002784), gamma-aminobutyric acid (MESH:D005680), ISM (MESH:C000616632), Metformin (MESH:D008687), tyrosine (MESH:D014443)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** p.T46R, rs12970134, Rs17773430, p.Met134Ile, rs17782313, p.Phe62Cys, c.5-5del, rs571312, Ser/Thr, Rs7359397, Rs34114122, c.3-7del, T377N, p.V103Afs*5, p.G52R, p.Pro195Leu, p.Asp294Glu, c.55del, c.1765-8G>A, I251L, p.Ala70Thr, p.Ser19Alafs*34, c.308delT, p.Arg224Trp, p.Gly31Val, rs7498665, p.Thr6Lys, p.Val81Ile, p.T714A, p.Lys102X, p.H323Y, c.380C>T, p.Arg525Gln, c.335C>T, p.A40S, p.Pro72Ser, p.Ile183Asn, Rs8192678, p.Asn77Ser

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939867/full.md

---
Source: https://tomesphere.com/paper/PMC12939867